IsomAb
Latest round
- Seed
Last raised
- Feb 2024
Total raised
- $0.9M
Investors
- 3
About IsomAb
a. IsomAb operates as a biotechnology company that focuses on developing isoform-specific disease-modifying antibody treatments for life-threatening diseases, with an initial focus on peripheral ischaemia. In February 2024, IsomAb Ltd. As of February 2024, Jackie Turnbull is the CEO of the company. The company’s product line includes ISM-001, an antibody therapeutic with a high affinity, neutralizing antibody that specifically binds VEGF165b. ISM-001 is helpful in the treatment of patients with type II diabetes mellitus disease.
Who invested in IsomAb
3 investors across 1 round
See all investors in IsomAb
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Feb 20, 2024
Amount
$0.9M
Investors
Questions about IsomAb
Who invested in IsomAb?
IsomAb has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IsomAb raised?
IsomAb has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did IsomAb last raise money?
IsomAb's most recent round on record is a Seed, in Feb 2024.
What does IsomAb do?
IsomAb is a biotechnology company.
Where is IsomAb headquartered?
IsomAb is headquartered in Nottingham, UK.
Which VCs invest in companies like IsomAb?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at IsomAb's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like IsomAb? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.